Mount Sinai: Prenatal Acetaminophen Exposure Increases Risks of Autism and ADHD in Children, According to Analysis of 46 Global Studies – Gateway Hispanic

As public alarm grows regarding neurodevelopmental disorders, a recent investigation by Mount Sinai Hospital has reignited discussions around the safety of acetaminophen, widely known as paracetamol or Tylenol. This over-the-counter pain reliever is commonly utilized by over half of expectant mothers globally for relief from discomfort and fever.

According to research, prenatal acetaminophen exposure is implicated in elevated risks for autism and attention deficit hyperactivity disorder (ADHD) in children.

The analysis, published in August 2025 in the journal Environmental Health, synthesized findings from 46 prior studies conducted by international teams. It employed the Navigation Guide methodology, a stringent framework for assessing environmental data. The report reveals a troubling correlation: prenatal use of acetaminophen heightens the risk of autism by 19% (odds ratio of 1.19) and ADHD by 26% (odds ratio of 1.26).

Dr. Diddier Prada, who led the study at the Icahn School of Medicine at Mount Sinai, stated: “Our findings indicate that higher-quality studies tend to illustrate a connection between prenatal acetaminophen exposure and increased risks of autism and ADHD.”

This comprehensive analysis included investigations into 20 studies regarding ADHD, eight on autism, and 18 focusing on other neurodevelopmental disorders. Notably, a 2019 study from Johns Hopkins—analyzing umbilical cord blood samples from 996 children—reported that elevated acetaminophen levels more than tripled the autism risk (up to 3.62 times) and doubled the ADHD risk (up to 2.86 times).

Longitudinal tracking of children for an average of 8.9 years highlighted alarming trends. A subsequent study funded by the NIH in 2025 reiterated these patterns: mid-range exposure linked to a 2.26 times greater ADHD risk and a 2.14 times increase in autism risk.

Data derived from prominent cohorts such as the Boston Birth Cohort and the Nurses’ Health Study II suggests that the biological mechanisms at play are concerning. Acetaminophen is capable of crossing the placental barrier, which could lead to oxidative stress, hormonal disruption, and epigenetic alterations that threaten fetal brain development. The risk appears to amplify during the third trimester, a critical period of rapid brain development.

In response to these findings, the U.S. FDA issued guidelines in September 2025 urging clinicians to revise product labels for acetaminophen, citing “accumulated evidence” linking it with autism and ADHD. Clinicians are now encouraged to recommend minimal doses and short-term use.

This development coincided with remarks by President Donald Trump and Health Secretary Robert F. Kennedy Jr. At a White House briefing on September 22, Trump cautioned, “Acetaminophen during pregnancy can significantly increase the risk of autism. Avoid Tylenol wherever possible.” Kennedy echoed this sentiment, declaring, “The Trump administration believes that better health doesn’t always mean popping more pills.”

Both leaders connected these findings to the so-called “autism epidemic,” which has surged nearly 400% since 2000, impacting 1 in 31 children in the U.S. They introduced a public health campaign and expedited the approval process for leucovorin, a medication aimed at treating folate deficiencies associated with autism.

However, the quandary for expectant mothers remains profound. Acetaminophen is generally the only over-the-counter analgesic sanctioned for use during pregnancy. Alternates like ibuprofen or aspirin carry heightened risks of miscarriage, heart defects, and bleeding. Leaving fevers untreated poses its own threats, including neural tube defects, preterm birth, and a potential increase in autism risks.

Compelling data from conflicting research only exacerbate the confusion surrounding acetaminophen use. A 2024 cohort study of 2.48 million Swedish children, employing sibling controls to remove genetic variances, found no causal link; the disparities in autism risks were minor (1.33% vs. 1.53%) and for ADHD (2.46% vs. 2.87%).

A European meta-analysis from 2021 studying six cohorts—comprising 73,881 children—indicated raised odds only with prenatal, not postnatal exposure. Critics, however, caution against potential biases, claiming that mothers predisposed to autism often report higher analgesic use due to increased pain experiences.

In contrast, agencies such as the EMA and relevant Australian and British bodies have staunchly rejected assertions made by Trump: “There is no substantiated causal link.” Kenvue, the manufacturer of Tylenol, voiced concerns over the confusion such claims may cause for expectant mothers, cautioning against health risks arising from misinformation.

Studies in Spain and Latin America, such as ISGlobal’s (2021) investigation involving 70,000 European children, suggest associations but advocate against panic. Experts like Yale’s Zeyan Liew advise: “No causality has been established. Consult your healthcare provider and use low doses for short durations when necessary.” The prevailing consensus suggests that for moderate use, the benefits of acetaminophen tend to outweigh the theoretical risks.

This scientific breakthrough, supported by the impactful leadership of Donald Trump and Robert F. Kennedy Jr., signals a determined commitment to public health. Their audacious challenge to conventional health narratives aims to safeguard future generations by illuminating the potential dangers of acetaminophen.

In an era where faith in medical establishments is wavering, their cautious advocacy serves as an act of responsibility prioritizing the welfare of the most defenseless: the unborn.

In reflection, this debate transcends mere science; it highlights the influence of leaders who dare to question prevailing norms. Kennedy’s relentless pursuit of health advocacy is inciting a movement towards increased public awareness, safer alternatives, and further research.

Read more:

About The Author